BrightInsight and AstraZeneca Collaborate to Enhance Disease Management
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant…
BrightInsight Accelerates Time to Market for the AstraZeneca AMAZE Disease Management Platform Within a Regulatory-Compliant…
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX…
Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or…
SAFEbody technology enables precision masking of antibodies for enhanced safety SAN FRANCISCO and SUZHOU, China,…
Phase 2 AFFINITY Trial of Atrasentan for Patients with Glomerular Diseases Also on Track to…
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) — Better Choice Company (OTCQX: BTTR) (“Better Choice”…
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE”…
-Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to…
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting LYON, France and…
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic…
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA®…
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab…
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
Topline Results Expected in the Second Quarter of 2021 SAN DIEGO, March 16, 2021 (GLOBE…
Programs receiving funding include those developing company’s proprietary cryopreserved NK and gamma delta T-cell candidates…
– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set…
Management to host conference call and webcast on March 23rd at 5:00 pm EDT /…
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia…
SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics (NASDAQ: VTGN), a…
ROCKVILLE, Md., March 16, 2021 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics (ICT), a clinical stage…